,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,422,1,5,,17405685,6112,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
1,429,1,5,,17405685,6112,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
2,429,1,5,,17405685,6112,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
3,436,2,1,,17405685,6112,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
4,547,1,4,,17405685,6112,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
5,694,1,1,,17405685,6112,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
6,732,1,2,,17405685,6112,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
7,880,2,1,,50107042,6112,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
8,880,2,1,,50107042,6112,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
9,894,2,1,,50107042,6112,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
10,940,1,2,,17405685,6112,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
11,1030,2,1,,50107042,6112,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
12,1379,1,2,,50107042,6112,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
13,1422,1,1,,17405685,6112,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
14,1454,1,1,,50107042,6112,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
15,1457,1,1,,50107042,6112,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
16,1458,1,1,,50107042,6112,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
17,1459,1,1,,50107042,6112,Inconclusive,27436948.0,4000.0,35.4813,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
18,1460,1,3,,50107042,6112,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
19,1461,1,2,,50107042,6112,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
20,1463,1,1,,50107042,6112,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
21,1467,1,3,,50107042,6112,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
22,1468,1,1,,50107042,6112,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
23,1469,1,1,,29215172,6112,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
24,1469,1,1,,50107042,6112,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
25,1476,2,1,,50107042,6112,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
26,1477,1,1,,29215172,6112,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
27,1477,1,1,,50107042,6112,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
28,1478,2,1,,50107042,6112,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
29,1479,1,2,,29215172,6112,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
30,1479,1,2,,50107042,6112,Inconclusive,189491771.0,7068.0,0.8913,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
31,1487,1,1,,50107042,6112,Inconclusive,27436948.0,4000.0,0.3548,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
32,1490,2,1,,29215172,6112,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
33,1519,1,3,,50107042,6112,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
34,1705,1,2,,50107042,6112,Inactive,6980812.0,,,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
35,1707,1,3,,50107042,6112,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
36,1708,1,3,,50107042,6112,Inconclusive,405898.0,,0.8913,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
37,1766,1,1,,29215172,6112,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
38,1766,1,1,,29215172,6112,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
39,1766,1,1,,50107042,6112,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
40,1766,1,1,,50107042,6112,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
41,1768,1,1,,29215172,6112,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
42,1768,1,1,,29215172,6112,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
43,1768,1,1,,50107042,6112,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
44,1768,1,1,,50107042,6112,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
45,1815,1,1,,50107042,6112,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
46,1816,1,1,,50107042,6112,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
47,1828,2,1,,50107042,6112,Inactive,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
48,1865,1,1,,50107042,6112,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
49,1876,1,1,,50107042,6112,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
50,1877,1,1,,50107042,6112,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
51,1882,1,1,,50107042,6112,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
52,1883,1,1,,50107042,6112,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
53,1886,1,1,,50107042,6112,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
54,1948,1,1,,50107042,6112,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
55,1967,1,1,,50107042,6112,Inconclusive,4505907.0,5376.0,33.8078,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
56,2101,1,1,,29215172,6112,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
57,2101,1,1,,50107042,6112,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
58,2107,1,1,,29215172,6112,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
59,2107,1,1,,50107042,6112,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
60,2112,1,1,,29215172,6112,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
61,2112,1,1,,50107042,6112,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
62,2147,1,1,,50107042,6112,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
63,2314,1,2,,29215172,6112,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
64,2314,1,2,,29215172,6112,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
65,2315,1,2,,29215172,6112,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
66,2315,1,2,,29215172,6112,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
67,2323,1,1,,50107042,6112,Inactive,254220970.0,,,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
68,2326,1,1,,50107042,6112,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
69,2353,1,3,,50107042,6112,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
70,2364,1,2,,50107042,6112,Inconclusive,4557365.0,641.0,7.9433,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
71,2451,1,2,,29215172,6112,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
72,2451,1,2,,50107042,6112,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
73,2472,1,2,,29215172,6112,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
74,2517,2,1,,29215172,6112,Inconclusive,6980812.0,,0.8913,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
75,2517,2,1,,50107042,6112,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
76,2528,1,2,,29215172,6112,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
77,2528,1,2,,50107042,6112,Inconclusive,4557365.0,641.0,7.9433,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
78,2546,1,1,,29215172,6112,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
79,2549,1,1,,29215172,6112,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
80,2549,1,1,,50107042,6112,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
81,2551,1,1,,29215172,6112,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
82,2660,1,1,,90340763,6112,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
83,2662,2,1,,50107042,6112,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
84,2666,1,1,,90340763,6112,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
85,2667,1,1,,90340763,6112,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
86,2668,1,1,,90340763,6112,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
87,2675,1,1,,50107042,6112,Unspecified,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
88,2732,1,1,,17405685,6112,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
89,2774,1,3,,92303296,6112,Inactive,,,,,LOPAC Circadian Assay,Screening,,
90,27921,3,4,,103372397,6112,Unspecified,,,,,The compound was evaluated for lipophilicity.,Other,11708933.0,
91,84280,6,2,,103372397,6112,Active,,,19.6,IC50,Neuroprotective effect was measured by its ability to protect mouse hippocampal neuronal HT-22 cell lines from oxidative stress caused by glutamate,Confirmatory,12031315.0,
92,127631,6,2,,103372397,6112,Unspecified,,,121.6,EC50,Ability for prevention of GSH depletion was measured in mouse,Confirmatory,12031315.0,
93,147106,8,4,,103372397,6112,Inactive,,,,,In vitro inhibition concentration was evaluated on the effect of conversion by Nitric Oxide synthase of [3H]L-arginine into [3H]L-citrulline; Not active up to 100 uM,Other,12031315.0,
94,196890,3,3,,103372397,6112,Unspecified,,,,,Effect on in vitro myocardial electrical activity (arrhythmia score) at 5 uM,Other,11708933.0,
95,196903,3,3,,103372397,6112,Unspecified,,,,,"Effect on in vitro accumulation of MDA content in heart, at conc of 5 uM",Other,11708933.0,
96,197084,6,2,,103372397,6112,Unspecified,,,1000.0,IC50,Inhibition of in vitro peroxidation (LP) of rat Hepatic microsomal membrane lipid,Confirmatory,11708933.0,
97,197086,6,2,,103372397,6112,Unspecified,,,400.0,IC50,Evaluated for the interaction with 0.2 mM of the stable free radical DPPH.,Confirmatory,11708933.0,
98,239826,3,10,,103372397,6112,Inconclusive,116241241.0,147.0,,,Equilibrium dissociation constant was evaluated by radio-receptor binding assays using [3H]prazosin to label cloned human alpha 1b expressed in CHO cells; Not tested,Other,15633998.0,
99,239827,3,10,,103372397,6112,Inconclusive,1168243.0,146.0,,,Equilibrium dissociation constant was evaluated by radio-receptor binding assays using [3H]prazosin to label cloned human alpha 1d expressed in CHO cells; Not tested,Other,15633998.0,
100,239871,6,1,,103372397,6112,Unspecified,543734.0,24173.0,10.0,Kd,Blocking activity was assessed by antagonism of (-)-phenylephrine induced contraction of rat spleen (alpha1B adrenoceptor),Confirmatory,15633998.0,
101,239872,6,1,,103372397,6112,Unspecified,1168244.0,29413.0,10.0,Kd,Blocking activity was assessed by antagonism of (-)-noradrenaline induced contraction of rat thoracic aorta (Alpha-1D adrenoceptor),Confirmatory,15633998.0,
102,239873,6,1,,103372397,6112,Unspecified,1168247.0,29412.0,10.0,Kd,Blocking activity was assessed by antagonism of (-)-noradrenaline induced contraction of rat prostatic vas deferens (alpha1A adrenoceptor),Confirmatory,15633998.0,
103,239992,3,10,,103372397,6112,Inconclusive,1168246.0,148.0,,,Equilibrium dissociation constant was evaluated by radio-receptor binding assays using [3H]prazosin to label cloned human alpha 1a expressed in CHO cells; Not tested,Other,15633998.0,
104,241200,8,5,,103372397,6112,Unspecified,113037.0,43.0,1000.0,IC50,Inhibitory concentration against human recombinant acetylcholinesterase,Confirmatory,15658850.0,
105,241230,8,5,,103372397,6112,Unspecified,116353.0,590.0,1000.0,IC50,Inhibitory concentration against human recombinant butyrylcholinesterase,Confirmatory,15658850.0,
106,248861,6,2,,103372397,6112,Unspecified,,,54.86,IC50,Antioxidant activity against formation of ROS was determined in t-BuOOH treated LNCaP cells after 24 hr of incubation with compounds (1-100 uM),Confirmatory,15633998.0,
107,248936,8,2,,103372397,6112,Inactive,,,,,Antiproliferative activity was determined by colorimetric MTS assay in LNCaP cells after 72 hr of incubation with compounds (1-100 uM); Not active at 100 uM,Other,15633998.0,
108,250064,3,3,,103372397,6112,Unspecified,,,,,Percentage increase of intracellular reactive oxygen species in neuronal cells at 0 uM,Other,15658850.0,
109,250065,3,3,,103372397,6112,Unspecified,,,,,Percentage increase of intracellular reactive oxygen species in neuronal cells at 1 uM,Other,15658850.0,
110,250066,3,3,,103372397,6112,Unspecified,,,,,Percentage increase of intracellular reactive oxygen species in neuronal cells at 5 uM,Other,15658850.0,
111,250069,3,3,,103372397,6112,Unspecified,,,,,Percentage increase of intracellular reactive oxygen species in neuronal cells at 10 uM,Other,15658850.0,
112,250070,3,3,,103372397,6112,Unspecified,,,,,Percentage increase of intracellular reactive oxygen species in neuronal cells at 50 uM,Other,15658850.0,
113,250074,3,3,,103372397,6112,Unspecified,,,,,Percentage increase of intracellular reactive oxygen species in neuronal cells at 0.1 uM,Other,15658850.0,
114,250075,3,3,,103372397,6112,Unspecified,,,,,Percentage increase of intracellular reactive oxygen species in neuronal cells at 0.5 uM,Other,15658850.0,
115,264479,4,1,,103372397,6112,Unspecified,,,40738000.0,Ki,"Lipophilicity, log k'w of the compound",Confirmatory,16640342.0,
116,264480,3,3,,103372397,6112,Unspecified,,,,,Hydroxyl radical scavenging activity by ABTS competition assay per 30 mins at 1 umol/mL,Other,16640342.0,
117,264481,3,3,,103372397,6112,Active,,,,,Radical reducing potency by ABTS cation radical reduction assay per 30 mins at 1 umol/mL,Other,16640342.0,
118,264482,3,4,,103372397,6112,Unspecified,,,,,Inhibition of hydrogen peroxide-induced death of mixed cortical cells of E15 Sprague-Dawley rat embryo at 10 uM,Other,16640342.0,
119,264483,3,4,,103372397,6112,Unspecified,,,,,Inhibition of peroxynitrite-induced death of mixed cortical cells of E15 Sprague-Dawley rat embryo at 10 uM,Other,16640342.0,
120,264484,3,4,,103372397,6112,Unspecified,,,,,Inhibition of doxorubicin-induced death of mixed cortical cells of E15 Sprague-Dawley rat embryo at 10 uM,Other,16640342.0,
121,264485,3,3,,103372397,6112,Unspecified,,,,,Viability of rotifers against hydrogen peroxide toxicity at 10 uM,Other,16640342.0,
122,264486,3,3,,103372397,6112,Unspecified,,,,,Viability of rotifers against doxorubicin toxicity at 10 uM,Other,16640342.0,
123,286751,3,9,,103372397,6112,Unspecified,126398.0,547923.0,,,Inhibition of soybean lipoxygenase at 0.1 mM,Other,17444626.0,
124,286752,3,3,,103372397,6112,Unspecified,,,,,"Inhibition of carrageenan-induced Fischer 344 rat paw edema at 0.01 mmol/kg, ip",Other,17444626.0,
125,286753,4,3,,103372397,6112,Unspecified,,,,,Antioxidant activity assessed as DPPH reducing activity at 0.1 mM after 20 mins,Other,17444626.0,
126,286754,4,3,,103372397,6112,Unspecified,,,,,Antioxidant activity assessed as DPPH reducing activity at 0.1 mM after 60 mins,Other,17444626.0,
127,286755,4,3,,103372397,6112,Unspecified,,,,,Antioxidant activity assessed as DPPH reducing activity at 0.5 mM after 20 mins,Other,17444626.0,
128,286756,4,3,,103372397,6112,Unspecified,,,,,Antioxidant activity assessed as DPPH reducing activity at 0.5 mM after 60 mins,Other,17444626.0,
129,286757,4,3,,103372397,6112,Unspecified,,,,,Antioxidant activity assessed as DMSO hydroxyl radical scavenging activity at 0.1 mM,Other,17444626.0,
130,289322,6,2,,103372397,6112,Active,,,2.4,IC50,Hypochlorous acid scavenging activity assessed as inhibition of DHR oxidation,Confirmatory,17624791.0,
131,314091,11,2,,103372397,6112,Active,113037.0,43.0,0.001,IC50,Inhibition of human AchE,Confirmatory,18181565.0,
132,314093,3,9,,103372397,6112,Unspecified,113037.0,43.0,,,Inhibition of human AchE-induced amyloid beta aggregation at 100 uM,Other,18181565.0,
133,336478,3,7,,103372397,6112,Unspecified,,,,,Inhibition of COX2 at 100 uM by scintillation proximity assay,Other,12444669.0,
134,347225,6,2,,103372397,6112,Active,,,11.0,IC50,Antioxidant activity assessed as hydroxyl radical scavenging activity,Confirmatory,19097798.0,
135,363800,6,7,,103372397,6112,Unspecified,166897622.0,282022.0,,IC50,Inhibition of bovine COX1,Confirmatory,17976864.0,
136,363802,9,5,,103372397,6112,Unspecified,3915797.0,5743.0,,IC50,Inhibition of human COX2,Confirmatory,17976864.0,
137,363804,6,2,,103372397,6112,Unspecified,,,,IC50,Inhibition of bovine 5LOX,Confirmatory,17976864.0,
138,363806,6,2,,103372397,6112,Unspecified,,,,IC50,Antioxidant activity assessed as hydroxyl radical scavenging activity,Confirmatory,17976864.0,
139,383202,3,3,,103372397,6112,Unspecified,,,,,Antioxidant scavenging activity against AAPH-induced peroxyl radical assessed as trolox equivalent per uM of compound by ORAC-fluorescein assay,Other,18343673.0,
140,426422,4,3,,103372397,6112,Unspecified,,,,,Antioxidant activity against hydroxyl radical assessed as inhibition of formaldehyde production at 0.1 mM after 30 mins relative to DMSO,Other,19232783.0,
141,426426,5,3,,103372397,6112,Unspecified,,,,,Inhibition of soybean lipoxygenase assessed as conversion of sodium linoleate to 13-hydroperoxylinoleic acid at 0.1 mM,Other,19232783.0,
142,426427,5,3,,103372397,6112,Unspecified,,,,,"In vivo antiinflammatory activity in Fisher 344 rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, ip administered simultaneously with carrageenan measured after 3.5 hrs",Other,19232783.0,
143,426430,3,3,,103372397,6112,Unspecified,,,,,Antioxidant activity assessed as reduction of DPPH activity at 0.1 mM after 20 mins,Other,19232783.0,
144,426431,3,3,,103372397,6112,Unspecified,,,,,Antioxidant activity assessed as reduction of DPPH activity at 0.1 mM after 60 mins,Other,19232783.0,
145,426432,4,3,,103372397,6112,Unspecified,,,,,Antioxidant activity assessed as reduction of DPPH activity at 0.5 mM after 20 mins,Other,19232783.0,
146,426433,4,3,,103372397,6112,Unspecified,,,,,Antioxidant activity assessed as reduction of DPPH activity at 0.5 mM after 60 mins,Other,19232783.0,
147,453279,5,2,,103372397,6112,Active,,,1.95,IC50,Antioxidant activity assessed as hypochlorous acid scavenging activity by fluorescent rhodamine formation assay,Confirmatory,19781949.0,
148,463096,1,1,,50107042,6112,Inactive,,,,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
149,463097,1,1,,50107042,6112,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
150,463106,1,2,,90340763,6112,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
151,463189,1,1,,53778235,6112,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
152,481537,3,4,,103372397,6112,Unspecified,,,,,Induction of apoptosis in human SMMC7721 cells at 5 mM after 96 hrs,Other,20403695.0,
153,481538,3,4,,103372397,6112,Unspecified,,,,,Growth inhibition of human FADU cells at 10 uM,Other,20403695.0,
154,481539,3,4,,103372397,6112,Unspecified,,,,,Growth inhibition of human SCC9 cells at 10 uM,Other,20403695.0,
155,481540,3,4,,103372397,6112,Unspecified,,,,,Growth inhibition of human SCC25 cells at 10 uM,Other,20403695.0,
156,481541,3,3,,103372397,6112,Unspecified,,,,,Growth inhibition of human Detroit 562 cells at 10 uM,Other,20403695.0,
157,481542,5,2,,103372397,6112,Unspecified,,,250.0,EC50,Induction of apoptosis in human HT-29 cells,Confirmatory,20403695.0,
158,481543,6,2,,103372397,6112,Unspecified,,,,,Toxicity in rat,Other,20403695.0,
159,481545,3,4,,103372397,6112,Unspecified,,,,,Cytotoxicity against human NCI-H460 cells assessed as growth inhibition at 100 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
160,481546,3,4,,103372397,6112,Unspecified,,,,,Cytotoxicity against human NCI-H460 cells assessed as growth inhibition at 10 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
161,481547,3,4,,103372397,6112,Unspecified,,,,,Cytotoxicity against human NCI-H460 cells assessed as growth inhibition at 1 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
162,481548,3,4,,103372397,6112,Unspecified,,,,,Cytotoxicity against human NCI-H460 cells assessed as growth inhibition at 0.1 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
163,481549,3,4,,103372397,6112,Unspecified,,,,,Cytotoxicity against human HO8910 cells assessed as growth inhibition at 100 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
164,481550,3,4,,103372397,6112,Inactive,,,,,Cytotoxicity against human HO8910 cells assessed as growth inhibition at 10 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
165,481551,3,4,,103372397,6112,Unspecified,,,,,Cytotoxicity against human HO8910 cells assessed as growth inhibition at 1 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
166,481552,3,4,,103372397,6112,Unspecified,,,,,Cytotoxicity against human HO8910 cells assessed as growth inhibition at 0.1 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
167,481553,3,4,,103372397,6112,Unspecified,,,,,Cytotoxicity against human KB cells assessed as growth inhibition at 100 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
168,481554,3,4,,103372397,6112,Unspecified,,,,,Cytotoxicity against human KB cells assessed as growth inhibition at 10 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
169,481555,3,4,,103372397,6112,Unspecified,,,,,Cytotoxicity against human KB cells assessed as growth inhibition at 1 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
170,481556,3,4,,103372397,6112,Unspecified,,,,,Cytotoxicity against human KB cells assessed as growth inhibition at 0.1 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
171,481557,3,4,,103372397,6112,Unspecified,,,,,Cytotoxicity against human Bel7402 cells assessed as growth inhibition at 100 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
172,481558,3,4,,103372397,6112,Unspecified,,,,,Cytotoxicity against human Bel7402 cells assessed as growth inhibition at 10 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
173,481559,3,4,,103372397,6112,Unspecified,,,,,Cytotoxicity against human Bel7402 cells assessed as growth inhibition at 1 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
174,481560,3,4,,103372397,6112,Inactive,,,,,Cytotoxicity against human Bel7402 cells assessed as growth inhibition at 0.1 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
175,481561,3,4,,103372397,6112,Inconclusive,,,,,Cytotoxicity against human PC3 cells assessed as growth inhibition at 100 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
176,481562,3,4,,103372397,6112,Inconclusive,,,,,Cytotoxicity against human PC3 cells assessed as growth inhibition at 10 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
177,481563,3,4,,103372397,6112,Inconclusive,,,,,Cytotoxicity against human PC3 cells assessed as growth inhibition at 1 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
178,481564,3,4,,103372397,6112,Inconclusive,,,,,Cytotoxicity against human PC3 cells assessed as growth inhibition at 0.1 ug/ml after 24 hrs by MTT assay,Other,20403695.0,
179,485281,1,1,,29215172,6112,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
180,485290,1,1,,29215172,6112,Inconclusive,20150581.0,,63.0957,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
181,485290,1,1,,50107042,6112,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
182,485295,1,2,,90340763,6112,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
183,485297,1,1,,90340763,6112,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
184,485298,1,1,,90340763,6112,Inactive,,,4.6109,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
185,485313,1,2,,90340763,6112,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
186,485314,1,1,,50107042,6112,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
187,485342,1,2,,90340763,6112,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
188,485345,1,2,,90340763,6112,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
189,485366,1,2,,90340763,6112,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
190,485368,1,2,,90340763,6112,Inconclusive,72386991.0,3656265.0,15.1014,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
191,488745,1,4,,50107042,6112,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
192,488752,1,4,,50107042,6112,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
193,488772,1,1,,90340763,6112,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
194,488773,1,2,,90340763,6112,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
195,488816,1,1,,90340763,6112,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
196,488837,1,1,,90340763,6112,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
197,488949,1,2,,50107042,6112,Inactive,41055989.0,54737.0,50.1187,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
198,488949,1,2,,90340763,6112,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
199,488953,1,1,,90340763,6112,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
200,488978,1,1,,90340763,6112,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
201,488979,1,1,,50107042,6112,Inactive,74315350.0,7442.0,,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
202,488980,1,1,,50107042,6112,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
203,488981,1,1,,90340763,6112,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
204,488982,1,1,,90340763,6112,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
205,488983,1,1,,90340763,6112,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
206,493106,1,1,,90340763,6112,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
207,493107,1,1,,90340763,6112,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
208,493127,1,1,,50107042,6112,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
209,493153,1,1,,90340763,6112,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
210,493153,1,1,,90340763,6112,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
211,493164,1,2,,90340763,6112,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
212,493164,1,2,,90340763,6112,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
213,493164,1,2,,90340763,6112,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
214,493189,1,1,,50107042,6112,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
215,504327,1,1,,29215172,6112,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
216,504327,1,1,,90340763,6112,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
217,504332,1,1,,50107042,6112,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
218,504332,1,1,,90340763,6112,Inconclusive,168985070.0,,37.6858,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
219,504364,1,1,,50107042,6112,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
220,504536,1,1,,90340763,6112,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
221,504547,1,1,,90340763,6112,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
222,504548,1,2,,90340763,6112,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
223,504810,1,2,,90340763,6112,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
224,504812,1,2,,90340763,6112,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
225,504821,1,1,,50107042,6112,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
226,504836,1,2,,90340763,6112,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
227,504845,1,1,,90340763,6112,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
228,504847,1,1,,29215172,6112,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
229,504847,1,1,,90340763,6112,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
230,504865,1,1,,90340763,6112,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
231,521220,3,3,,103372397,6112,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
232,540256,1,2,,50107042,6112,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
233,540256,1,2,,90340763,6112,Inconclusive,,,5.8024,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
234,540276,1,2,,29215172,6112,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
235,540276,1,2,,50107042,6112,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
236,540276,1,2,,50107043,6112,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
237,540276,1,2,,90340763,6112,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
238,567076,1,4,,103372397,6112,Unspecified,,,,,Growth inhibition of human HT-29 cells at 100 uM after 24 hrs by BrdU-ELISA assay,Other,21111517.0,
239,567077,1,4,,103372397,6112,Unspecified,,,,,Growth inhibition of human HT-29 cells at 150 uM after 24 hrs by BrdU-ELISA assay,Other,21111517.0,
240,567078,1,4,,103372397,6112,Unspecified,,,,,Growth inhibition of human HT-29 cells at 300 uM after 24 hrs by BrdU-ELISA assay,Other,21111517.0,
241,567079,1,4,,103372397,6112,Unspecified,,,,,Growth inhibition of human HT-29 cells at 100 uM after 48 hrs by BrdU-ELISA assay,Other,21111517.0,
242,567080,1,4,,103372397,6112,Unspecified,,,,,Growth inhibition of human HT-29 cells at 150 uM after 48 hrs by BrdU-ELISA assay,Other,21111517.0,
243,567081,1,4,,103372397,6112,Unspecified,,,,,Growth inhibition of human HT-29 cells at 300 uM after 48 hrs by BrdU-ELISA assay,Other,21111517.0,
244,567082,1,4,,103372397,6112,Unspecified,,,,,Induction of cell cycle arrest in human HT-29 cells assessed as accumulation at G0/G1 phase at 100 uM after 24 hrs by flow cytometry (Rvb = 61.4+/-1.1%),Other,21111517.0,
245,567083,1,4,,103372397,6112,Unspecified,,,,,Induction of cell cycle arrest in human HT-29 cells assessed as accumulation at G0/G1 phase at 150 uM after 24 hrs by flow cytometry (Rvb = 61.4+/-1.1%),Other,21111517.0,
246,567084,1,4,,103372397,6112,Unspecified,,,,,Induction of cell cycle arrest in human HT-29 cells assessed as accumulation at G0/G1 phase at 300 uM after 24 hrs by flow cytometry (Rvb = 61.4+/-1.1%),Other,21111517.0,
247,567085,1,4,,103372397,6112,Unspecified,,,,,Induction of cell cycle arrest in human HT-29 cells assessed as accumulation at S phase at 100 uM after 24 hrs by flow cytometry (Rvb = 21+/-0.9%),Other,21111517.0,
248,567086,1,4,,103372397,6112,Unspecified,,,,,Induction of cell cycle arrest in human HT-29 cells assessed as accumulation at S phase at 150 uM after 24 hrs by flow cytometry (Rvb = 21+/-0.9%),Other,21111517.0,
249,567087,1,4,,103372397,6112,Unspecified,,,,,Induction of cell cycle arrest in human HT-29 cells assessed as accumulation at S phase at 300 uM after 24 hrs by flow cytometry (Rvb = 21+/-0.9%),Other,21111517.0,
250,567088,1,4,,103372397,6112,Unspecified,,,,,Induction of cell cycle arrest in human HT-29 cells assessed as accumulation at G2/M phase at 100 uM after 24 hrs by flow cytometry (Rvb = 17.6+/-1%),Other,21111517.0,
251,567089,1,4,,103372397,6112,Unspecified,,,,,Induction of cell cycle arrest in human HT-29 cells assessed as accumulation at G2/M phase at 150 uM after 24 hrs by flow cytometry (Rvb = 17.6+/-1%),Other,21111517.0,
252,567090,1,4,,103372397,6112,Unspecified,,,,,Induction of cell cycle arrest in human HT-29 cells assessed as accumulation at G2/M phase at 300 uM after 24 hrs by flow cytometry (Rvb = 17.6+/-1%),Other,21111517.0,
253,588349,1,1,,90340763,6112,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
254,588378,1,1,,90340763,6112,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
255,588453,1,1,,50107042,6112,Inactive,8659577.0,58819.0,89.1251,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
256,588453,1,1,,90340763,6112,Inactive,8659577.0,58819.0,0.8913,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
257,588456,1,1,,90340763,6112,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
258,588579,1,1,,29215172,6112,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
259,588579,1,1,,90340763,6112,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
260,588590,1,1,,50107042,6112,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
261,588591,1,1,,50107042,6112,Inconclusive,5729982.0,5429.0,0.2512,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
262,588795,1,1,,90340763,6112,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
263,588834,2,1,,50107042,6112,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
264,590976,1,4,,103372397,6112,Unspecified,,,,,Induction of amyloid beta 40 fibril disassembly at 1:2 compound:amyloid-beta ratio,Other,21435875.0,
265,591507,1,3,,103372397,6112,Unspecified,,,,,"Antihyperalgesic activity in rat assessed as reversal of oxaliplatin-induced mechanical hyperalgesia at 50 to 100 mg.kg, iv by paw pressure test",Other,21381762.0,
266,602332,1,1,,29215172,6112,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
267,602332,1,1,,90340763,6112,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
268,624146,1,1,,90340763,6112,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
269,624147,1,1,,90340763,6112,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
270,624148,1,2,,90340763,6112,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
271,624149,1,1,,90340763,6112,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
272,624455,1,1,,90340763,6112,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
273,625144,5,5,,103372397,6112,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
274,625145,4,7,,103372397,6112,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
275,625146,5,5,,103372397,6112,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
276,625147,4,7,,103372397,6112,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
277,625148,4,7,,103372397,6112,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
278,625149,4,7,,103372397,6112,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
279,625150,5,5,,103372397,6112,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
280,625151,4,7,,103372397,6112,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
281,625152,4,7,,103372397,6112,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
282,625153,4,7,,103372397,6112,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
283,625154,4,7,,103372397,6112,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
284,625155,4,7,,103372397,6112,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
285,625156,1,9,,103372397,6112,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
286,625157,6,2,,103372397,6112,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
287,625158,3,4,,103372397,6112,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
288,625159,5,5,,103372397,6112,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
289,625160,1,9,,103372397,6112,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
290,625161,4,7,,103372397,6112,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
291,625162,4,7,,103372397,6112,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
292,625163,4,7,,103372397,6112,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
293,625164,1,6,,103372397,6112,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
294,625165,3,4,,103372397,6112,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
295,625166,3,4,,103372397,6112,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
296,625167,5,5,,103372397,6112,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
297,625168,4,7,,103372397,6112,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
298,625169,1,6,,103372397,6112,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
299,625170,3,4,,103372397,6112,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
300,625171,4,7,,103372397,6112,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
301,625172,4,7,,103372397,6112,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
302,625173,5,5,,103372397,6112,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
303,625174,5,5,,103372397,6112,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
304,625175,5,5,,103372397,6112,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
305,625176,1,9,,103372397,6112,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
306,625177,5,5,,103372397,6112,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
307,625178,5,5,,103372397,6112,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
308,625179,1,9,,103372397,6112,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
309,625180,5,5,,103372397,6112,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
310,625181,5,5,,103372397,6112,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
311,625182,5,5,,103372397,6112,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
312,625183,5,5,,103372397,6112,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
313,625184,5,5,,103372397,6112,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
314,625185,5,5,,103372397,6112,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
315,625186,5,5,,103372397,6112,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
316,625187,5,5,,103372397,6112,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
317,625188,1,9,,103372397,6112,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
318,625189,1,7,,103372397,6112,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
319,625190,4,5,,103372397,6112,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
320,625191,4,7,,103372397,6112,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
321,625192,4,7,,103372397,6112,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
322,625193,5,5,,103372397,6112,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
323,625194,4,7,,103372397,6112,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
324,625195,4,7,,103372397,6112,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
325,625196,5,6,,103372397,6112,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
326,625197,3,4,,103372397,6112,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
327,625198,4,7,,103372397,6112,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
328,625199,4,7,,103372397,6112,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
329,625200,4,7,,103372397,6112,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
330,625201,4,7,,103372397,6112,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
331,625202,4,7,,103372397,6112,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
332,625203,4,7,,103372397,6112,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
333,625204,4,7,,103372397,6112,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
334,625205,4,7,,103372397,6112,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
335,625206,4,7,,103372397,6112,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
336,625207,4,7,,103372397,6112,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
337,625208,5,5,,103372397,6112,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
338,625209,4,7,,103372397,6112,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
339,625210,3,4,,103372397,6112,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
340,625211,1,6,,103372397,6112,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
341,625212,3,4,,103372397,6112,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
342,625213,4,7,,103372397,6112,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
343,625214,1,9,,103372397,6112,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
344,625215,3,4,,103372397,6112,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
345,625216,3,4,,103372397,6112,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
346,625217,4,7,,103372397,6112,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
347,625218,4,7,,103372397,6112,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
348,625219,3,4,,103372397,6112,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
349,625220,4,7,,103372397,6112,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
350,625221,4,7,,103372397,6112,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
351,625222,4,7,,103372397,6112,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
352,625223,4,7,,103372397,6112,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
353,625224,3,4,,103372397,6112,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
354,625225,3,4,,103372397,6112,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
355,625226,4,7,,103372397,6112,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
356,625227,4,7,,103372397,6112,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
357,625228,4,7,,103372397,6112,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
358,625229,5,5,,103372397,6112,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
359,625230,1,6,,103372397,6112,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
360,625231,4,7,,103372397,6112,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
361,625232,1,9,,103372397,6112,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
362,625233,4,7,,103372397,6112,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
363,625234,3,4,,103372397,6112,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
364,625235,4,7,,103372397,6112,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
365,625236,5,5,,103372397,6112,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
366,625237,4,7,,103372397,6112,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
367,625238,4,7,,103372397,6112,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
368,625239,4,7,,103372397,6112,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
369,625240,1,9,,103372397,6112,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
370,625241,4,7,,103372397,6112,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
371,625242,4,7,,103372397,6112,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
372,625243,5,5,,103372397,6112,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
373,625244,5,5,,103372397,6112,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
374,625245,5,5,,103372397,6112,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
375,625246,1,9,,103372397,6112,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
376,625247,5,5,,103372397,6112,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
377,625248,5,5,,103372397,6112,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
378,625249,5,5,,103372397,6112,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
379,625250,5,5,,103372397,6112,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
380,625251,5,5,,103372397,6112,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
381,625252,4,7,,103372397,6112,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
382,625253,4,7,,103372397,6112,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
383,625254,4,7,,103372397,6112,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
384,625255,4,7,,103372397,6112,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
385,625256,4,7,,103372397,6112,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
386,625257,4,7,,103372397,6112,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
387,625258,4,7,,103372397,6112,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
388,625259,4,7,,103372397,6112,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
389,625260,3,4,,103372397,6112,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
390,625261,3,4,,103372397,6112,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
391,625262,3,4,,103372397,6112,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
392,625263,4,7,,103372397,6112,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
393,625264,3,4,,103372397,6112,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
394,625265,1,6,,103372397,6112,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
395,625266,3,4,,103372397,6112,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
396,625267,3,4,,103372397,6112,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
397,625268,4,2,,103372397,6112,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
398,625268,4,2,,103372397,6112,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
399,625268,4,2,,103372397,6112,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
400,625268,4,2,,103372397,6112,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
401,625269,4,7,,103372397,6112,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
402,625270,4,7,,103372397,6112,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
403,625271,5,5,,103372397,6112,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
404,625272,3,4,,103372397,6112,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
405,625273,4,6,,103372397,6112,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
406,625274,1,6,,103372397,6112,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
407,625275,3,4,,103372397,6112,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
408,625546,7,2,,103372397,6112,Unspecified,113037.0,43.0,1000.0,IC50,Inhibition of human serum recombinant AChE after 20 mins using acetylthiocholine iodide as a substrate by Ellman's assay,Confirmatory,21924801.0,
409,625547,7,2,,103372397,6112,Unspecified,116353.0,590.0,1000.0,IC50,Inhibition of human serum recombinant BChE after 20 mins using butyrylthiocholine iodide as a substrate by Ellman's assay,Confirmatory,21924801.0,
410,651635,1,3,,90340763,6112,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
411,651828,1,2,,121361803,6112,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
412,652106,1,1,,90340763,6112,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
413,668898,1,3,,103372397,6112,Unspecified,,,,,Inhibition of nitrite level in LPS-induced mouse RAW264.7 cells at 5 uM by Griess assay relative to LPS treated control,Other,21183258.0,
414,668899,1,3,,103372397,6112,Unspecified,,,,,Inhibition of nitrite level in LPS-induced mouse RAW264.7 cells at 50 uM by Griess assay relative to LPS treated control,Other,21183258.0,
415,668900,1,3,,103372397,6112,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells at 5 uM by MTT assay,Other,21183258.0,
416,668901,1,3,,103372397,6112,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells at 50 uM by MTT assay,Other,21183258.0,
417,687035,1,1,,163565083,6112,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
418,687037,1,3,,163565083,6112,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
419,720532,1,1,,29215172,6112,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
420,720533,1,1,,29215172,6112,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
421,720538,1,2,,90340763,6112,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
422,720559,1,2,,90340763,6112,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
423,720572,1,2,,90340763,6112,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
424,720573,1,2,,90340763,6112,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
425,743205,1,1,,90340763,6112,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
426,743205,1,1,,90340763,6112,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
427,743206,1,1,,90340763,6112,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
428,743206,1,1,,90340763,6112,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
429,743207,1,1,,90340763,6112,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
430,743207,1,1,,90340763,6112,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
431,743244,1,1,,90340763,6112,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
432,772966,1,1,,103372397,6112,Unspecified,,,,,Neuroprotective activity in 3 days postfertilized zebrafish larvae assessed as reduction of all-trans retinoic acid-induced apoptosis at 1 uM after 24 hrs by fluorescence microscopy,Other,23993774.0,
433,776254,1,1,,103372397,6112,Inactive,,,,,Induction of HDF proliferation at 0.1 mM after 48 hrs by MTT assay relative to control,Other,24090916.0,
434,776255,1,1,,103372397,6112,Unspecified,,,,,Cytotoxicity against HDF at 0.5 to 5 mM after 48 hrs by MTT assay,Other,24090916.0,
435,776261,1,1,,103372397,6112,Active,,,,,Inhibition of mushroom tyrosinase using L-DOPA as substrate at 2.5 mM preincubated for 10 to 15 mins prior to substrate addition by spectrophotometry,Other,24090916.0,
436,776264,1,1,,103372397,6112,Unspecified,,,,,Cytotoxicity against mouse B16F10 cells assessed as cell viability after 48 hrs by MTT assay,Other,24090916.0,
437,778728,1,1,,103372397,6112,Active,,,,,Antiapoptotic activity in rat L6 cells assessed as suppression of 23.5 mM D-glucose-induced JNK-46 phosphorylation at 2 mM after 30 mins by Western blot analysis,Other,23984871.0,
438,778729,1,1,,103372397,6112,Active,,,,,Antiapoptotic activity in rat L6 cells assessed as suppression of 23.5 mM D-glucose-induced JNK-54 phosphorylation at 2 mM after 30 mins by Western blot analysis,Other,23984871.0,
439,778732,1,1,,103372397,6112,Active,,,,,Antioxidant activity in rat L6 cells assessed as trolox equivalents of ABTS free radical scavenging activity at 2 mM after 2 hrs by ELISA reader analysis in presence of 23.5 mM D-glucose,Other,23984871.0,
440,778734,1,1,,103372397,6112,Active,,,,,Cytoprotective activity in rat L6 cells assessed as increase in glucose oxidase-reduced cell survival at 2 mM incubated for 30 mins prior to glucose oxidase challenge measured after 5 hrs by MTT assay in presence of 23.5 mM D-glucose,Other,23984871.0,
441,778736,1,1,,103372397,6112,Inactive,,,,,Effect on total GLUT4 level in rat L6 cells at 2 mM after 30 mins by Western blotting analysis,Other,23984871.0,
442,778737,1,1,,103372397,6112,Inactive,,,,,Effect on total GLUT1 level in rat L6 cells at 2 mM after 30 mins by Western blotting analysis,Other,23984871.0,
443,778740,1,1,,103372397,6112,Inactive,,,,,Effect on human myc epitope-tagged total GLUT4 level overexpressed in rat L6 cells at 2 mM after 30 mins by Western blotting analysis,Other,23984871.0,
444,778741,1,1,,103372397,6112,Inactive,,,,,Effect on human myc epitope-tagged total GLUT1 level overexpressed in rat L6 cells at 2 mM after 30 mins by Western blotting analysis,Other,23984871.0,
445,778746,1,5,,103372397,6112,Active,115502394.0,6513.0,,,Induction of human myc epitope-tagged GLUT1 translocation to plasma membrane overexpressed in rat L6 cells at 2 mM after 30 mins by immunocolorimetric analysis in presence of 23.5 mM D-glucose,Other,23984871.0,
446,778748,1,1,,103372397,6112,Inactive,,,,,Antihyperglycemic activity in rat L6 cells assessed as increase in [3H]dGlc uptake at 25 uM after 30 mins by liquid scintillation counting analysis,Other,23984871.0,
447,778750,1,1,,103372397,6112,Active,,,,,Antihyperglycemic activity in rat L6 cells assessed as increase in [3H]dGlc uptake at 2 mM after 30 mins by liquid scintillation counting analysis,Other,23984871.0,
448,977599,1,1,,103372397,6112,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
449,977602,1,2,,103372397,6112,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
450,1053268,1,4,,103372397,6112,Unspecified,3915797.0,5743.0,,,Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products at 500 uM preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method relative to control,Other,24088053.0,
451,1053269,1,4,,103372397,6112,Unspecified,317373262.0,5742.0,,,Inhibition of COX-1 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products at 500 uM preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method relative to control,Other,24088053.0,
452,1061203,1,1,,103372397,6112,Unspecified,,,,,"Cardioprotective activity in Sprague-Dawley rat model of myocardial ischemia-reperfusion injury assessed as reduction in MI/AR ratio at 1 to 10 mg/kg, iv bolus administered 15 mins prior to 30 mins LCX ligation by TTC staining-based fluorescence microscopy relative to placebo control",Other,24316353.0,
453,1079689,1,3,,103372397,6112,Unspecified,,,68.0,EC50,Cytoprotective activity in H2O2-induced human ECV304 cells assessed as proliferation rate incubated for 24 hrs prior to H2O2-challenge measured after 12 hrs by MTT assay,Confirmatory,,
454,1079690,1,2,,103372397,6112,Unspecified,,,,,Cytoprotective activity in H2O2-induced human ECV304 cells assessed as proliferation rate at 12.5 uM incubated for 24 hrs prior to H2O2-challenge measured after 12 hrs by MTT assay relative to control,Other,,
455,1079691,1,2,,103372397,6112,Unspecified,,,,,Cytoprotective activity in H2O2-induced human ECV304 cells assessed as proliferation rate at 25 uM incubated for 24 hrs prior to H2O2-challenge measured after 12 hrs by MTT assay relative to control,Other,,
456,1079692,1,2,,103372397,6112,Unspecified,,,,,Cytoprotective activity in H2O2-induced human ECV304 cells assessed as proliferation rate at 50 uM incubated for 24 hrs prior to H2O2-challenge measured after 12 hrs by MTT assay relative to control,Other,,
457,1079693,1,2,,103372397,6112,Unspecified,,,,,Cytoprotective activity in H2O2-induced human ECV304 cells assessed as proliferation rate at 100 uM incubated for 24 hrs prior to H2O2-challenge measured after 12 hrs by MTT assay relative to control,Other,,
458,1113238,1,2,,103372397,6112,Unspecified,,,,,Growth inhibition of Homo sapiens (human) NCI-H460 cells at 100 ug/ml by MTT assay,Other,,
459,1113239,1,2,,103372397,6112,Unspecified,,,,,Growth inhibition of Homo sapiens (human) KB cells at 100 ug/ml by MTT assay,Other,,
460,1113240,1,2,,103372397,6112,Unspecified,,,,,Growth inhibition of Homo sapiens (human) Bel7402 cells at 100 ug/ml by MTT assay,Other,,
461,1159580,2,1,,268738553,6112,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
462,1159607,2,1,,313041274,6112,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
463,1203897,1,1,,103372397,6112,Unspecified,,,,IC50,Cytotoxicity against human A549 cells after 48 hrs by SRB assay,Confirmatory,25874330.0,
464,1203902,1,1,,103372397,6112,Unspecified,,,,IC50,Cytotoxicity against human MRC5 cells after 48 hrs by SRB assay,Confirmatory,25874330.0,
465,1203907,1,1,,103372397,6112,Unspecified,,,,IC50,Cytotoxicity against human T24 cells after 48 hrs by SRB assay,Confirmatory,25874330.0,
466,1203914,1,1,,103372397,6112,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as inhibition fraction treated at 2:1 compound to GEM ratio after 48 hrs by SRB assay in presence of GEM,Other,25874330.0,
467,1203917,1,1,,103372397,6112,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as inhibition fraction treated at 5:1 compound to GEM ratio after 48 hrs by SRB assay in presence of GEM,Other,25874330.0,
468,1203920,1,1,,103372397,6112,Unspecified,,,,,"Cytotoxicity against human A549 cells assessed as inhibition fraction treated at sequential combination LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 compound to GEM ratio after 48 hrs by SRB assay in presence of GEM",Other,25874330.0,
469,1203922,1,1,,103372397,6112,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as dose reduction index ratio treated at simultaneous combination at 0.8 fraction inhibition after 48 hrs by SRB assay in presence of alpha-lipoic acid,Other,25874330.0,
470,1203924,1,1,,103372397,6112,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as dose reduction index ratio treated at simultaneous combination at 5:1 compound to GEM ratio after 48 hrs by SRB assay in presence of GEM,Other,25874330.0,
471,1203927,1,1,,103372397,6112,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as dose reduction index ratio treated at sequential combination at 2:1 compound to GEM ratio after 48 hrs by SRB assay in presence of GEM,Other,25874330.0,
472,1203928,1,1,,103372397,6112,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as dose reduction index ratio treated at sequential combination at 5:1 compound to GEM ratio after 48 hrs by SRB assay in presence of GEM,Other,25874330.0,
473,1203929,1,1,,103372397,6112,Unspecified,,,,,Cytotoxicity against human MRC5 cells assessed as dose reduction index ratio treated at sequential combination at 2:1 compound to GEM ratio after 48 hrs by SRB assay in presence of GEM,Other,25874330.0,
474,1203930,1,1,,103372397,6112,Unspecified,,,,,Cytotoxicity against human MRC5 cells assessed as dose reduction index ratio treated at sequential combination at 5:1 compound to GEM ratio after 48 hrs by SRB assay in presence of GEM,Other,25874330.0,
475,1203938,1,1,,103372397,6112,Active,,,,,Induction of H2O2 level in human A549 cells at 1 uM after 5 mins by flow cytometry,Other,25874330.0,
476,1215091,1,2,,103372397,6112,Unspecified,6093860.0,8856.0,,,Activation of human PXR expressed in human HepG2 (DPX-2) cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis,Other,20966043.0,
477,1215092,1,2,,103372397,6112,Unspecified,6093860.0,8856.0,,,Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 up to 46 uM after 24 hrs by luminescent analysis,Other,20966043.0,
478,1215093,1,2,,103372397,6112,Unspecified,10720242.0,84385.0,,,Activation of rat PXR expressed in human HepG2 cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis,Other,20966043.0,
479,1215094,1,2,,103372397,6112,Active,6093860.0,8856.0,2.8,EC50,Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay,Confirmatory,20966043.0,
480,1215095,1,2,,103372397,6112,Unspecified,6093860.0,8856.0,,,Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay relative to SR12813,Other,20966043.0,
481,1224818,1,1,,312345252,6112,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
482,1224819,1,1,,312345252,6112,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
483,1224820,1,1,,312345252,6112,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
484,1224821,1,1,,312345252,6112,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
485,1224822,1,1,,312345252,6112,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
486,1224823,1,1,,312345252,6112,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
487,1224857,2,1,,312345252,6112,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
488,1224859,2,1,,90340763,6112,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
489,1224905,2,1,,121361803,6112,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
490,1224905,2,1,,121361803,6112,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
491,1227389,1,1,,103372397,6112,Unspecified,,,,,Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells at 100 uM pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay,Other,,
492,1227390,1,1,,103372397,6112,Unspecified,,,,,Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells at 50 uM pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay,Other,,
493,1227391,1,1,,103372397,6112,Unspecified,,,,,Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells at 25 uM pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay,Other,,
494,1227392,1,1,,103372397,6112,Unspecified,,,,,Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells at 12.5 uM pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay,Other,,
495,1227393,1,1,,103372397,6112,Unspecified,,,68.0,EC50,Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay,Confirmatory,,
496,1259310,1,1,,332950219,6112,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
497,1259354,1,1,,348438286,6112,Inactive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
498,1259370,2,2,,124750257,6112,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
499,1259370,2,2,,124750257,6112,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
500,1259370,2,2,,124750257,6112,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
501,1259423,1,2,,354785697,6112,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
